LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more
LungLife AI Inc (LLAI) - Total Liabilities
Latest total liabilities as of June 2024: GBX1.13 Million GBX
Based on the latest financial reports, LungLife AI Inc (LLAI) has total liabilities worth GBX1.13 Million GBX as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LungLife AI Inc - Total Liabilities Trend (2018–2023)
This chart illustrates how LungLife AI Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LungLife AI Inc Competitors by Total Liabilities
The table below lists competitors of LungLife AI Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
G2M Cap Corp.
V:GTM-P
|
Canada | CA$10.72K |
|
Cue Health Inc.
NASDAQ:HLTHQ
|
USA | $84.20 Million |
|
LifeSafe Holdings PLC
LSE:LIFS
|
UK | GBX634.00K |
|
EMBRY HOLDINGS
BE:E3S
|
Germany | €704.09 Million |
|
MRC Allied Inc
PSE:MRC
|
Philippines | ₱1.46 Billion |
|
Marwyn Value Investors Limited
LSE:MVI
|
UK | GBX141.81K |
|
Synthesis Energy Systems Inc
PINK:SYNE
|
USA | $28.02K |
Liability Composition Analysis (2018–2023)
This chart breaks down LungLife AI Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LungLife AI Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LungLife AI Inc (2018–2023)
The table below shows the annual total liabilities of LungLife AI Inc from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | GBX1.61 Million | -14.41% |
| 2022-12-31 | GBX1.88 Million | +2.36% |
| 2021-12-31 | GBX1.84 Million | -7.87% |
| 2020-12-31 | GBX1.99 Million | -76.63% |
| 2019-12-31 | GBX8.53 Million | +123.22% |
| 2018-12-31 | GBX3.82 Million | -- |